How does one define 'value’ when considering a new technology? How does one create value when building a company on a novel platform? In today’s market, how does one price innovation in different healthcare systems?
At the 12th annual Business of Regenerative Medicine conference, biomedical researchers, CEOs, venture capitalists, and patient advocates will grapple with this complex and shifting landscape. Over two days of panel discussions, presentations, and networking, distinguished speakers will provide insights – as well as guardrails – for navigating the emerging industry of regenerative medicine.
We will explore how advances in cell and gene therapy, drug development, and bioengineering are moving from the lab to the patient, and what it will take to identify real, lasting value for both business and society. The Business of Regenerative Medicine conference series is organized jointly by the Harvard Stem Cell Institute, Case Western Reserve University, the Centre for Commercialization of Regenerative Medicine (Toronto), the Parker H. Petit Institute for Bioengineering & Bioscience at Georgia Tech, and the Penn Institute for Regenerative Medicine/Penn Medicine Center for Cellular Immunotherapies.